12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Chugai Pharmaceutical Co. Ltd, Eli Lilly sales and marketing update

Eli Lilly and Chugai terminated a deal to co-commercialize Evista raloxifene, effective Dec. 31. Following the termination, Lilly will be...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >